Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

I suspect NIAID is already looking into B/C. Auris

I assume NIAID learned, through the 2022 Brazilian study that:

In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans

http://www.ipharminc.com/press-release/2022/10/3/innovation-pharmaceuticals-announces-publication-of-scientific-article-on-the-antifungal-activity-of-brilacidin

I think they are also aware of these CDC facts;

There were at least 2,377 confirmed cases in the U.S. in 2022, according to CDC statistics. That total was a steep jump from the 1,474 cases in 2021 and continued a rapid increase from 2020, when there were just 757 confirmed cases.

Health officials said that the fungus’s resistance to antifungal medication is “particularly concerning” because those medications are often the first option for treatment, saying it necessitates research into better protection and prevention measures against the fungus.

“The rise in echinocandin-resistant cases and evidence of transmission is particularly concerning because echinocandins are first-line therapy for invasive Candida infections, including C auris,” a research paper into the spread of the fungus in the Annals of Internal Medicine said. “These findings highlight the need for improved detection and infection control practices to prevent spread of C auris.”

https://thehill.com/policy/healthcare/3909575-cdc-study-warns-of-dramatic-increase-in-deadly-fungus-across-us/?fbclid=IwAR3E-qeJjEmwCO10YIu4J3lL_62mlpHPK_Rz4Q-dXY7HIJWCvDt1AeE5jDg

I think it's reasonable to assume that NIAID is aware of the Brazilian research and CDC data showing "dramatic increases" in c. auris and Bs possibilities relative to same. I think it's a good bet NIAID is already on this.

Message in reply to:
CDC page regarding Candidia auris

https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html

Brilacidin for Candidia auris would be a good study for the George Mason and Rutgers biodefense labs.

GLTA, Farrell